A medicine, a food or a drink and feed which are effective for preventing and/or improving decline, occurring with age (senescence), in memory and learning ability are provided. A novel microorganism having the effect of preventing and/or improving decline, occurring with age (senescence,) in memory and learning ability is provided. More specifically, the microorganism is characterized by being a microorganism belonging to Lactobacillus, Bifidobacterium, Streptococcus, Leuconostoc or Pediococcus, more specifically a microorganism belonging to any of Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus gallinarum, Lactobacillus johnsonii, Lactobacillus delbrueckii subsp. delbrueckii, Bifidobacterium catenulatum, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophiles, Leuconostoc mesenteroides subsp. dextranicum, Leuconostoc lactis, Pediococcus acidilactici and Pediococcus pentosaceus.

The present disclosure relates to a novel strain of Lactobacillus fermentum LM1016 (KCCM12468P). The disclosed strain can be useful for treating or preventing cardiovascular diseases, obesity, fatty liver and/or diabetes. The present disclosure also relates to compositions comprising the strain. The compositions can be useful for medicines, health-functional foods, dairy products, fermented products, food additives, animal feeds, etc.

An isolated Lactobacillus mucosae (DPC6426) strain deposited with the National Collection of Industrial and Marine Bacteria Limited (NCIMB) on 27 Jul. 2012 under NCIMB Deposit Accession No. 42015.

The present invention relates to a microorganism belonging to the group of lactic acid bacteria characterized in that it is capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; and/or (ii) resistant to protease treatment; and/or (iii) calcium-dependent; and/or (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. Preferably, the specific binding can be assayed as follows: (a) growing said microorganism to stationary phase; (b) mixing said microorganism with Streptococcus mutans which has been grown to stationary phase; (c) incubating the mixture obtained in step (b) under conditions allowing the formation of aggregates of said microorganism and Streptococcus mutans and (d) detecting aggregates by the occurrence of a pellet.

Another aspect of the present invention is an analog or fragment of said microorganism which is thermally inactivated or lyophilized, wherein said analog or fragment retains the capability of specifically binding to Streptococcus mutans. In addition, the present invention encompasses compositions and additives for food, feed or drinks comprising the microorganism belonging to the group of lactic acid bacteria which specifically bind to Streptococcus mutans or an analog or fragment thereof. Moreover, uses of said microorganism or said analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing said compositions or food or feedstuff are provided by the present invention.

An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention.

Provided are uses of Bacteroides in preparation of a medicament. The medicament is for use in treatment or prevention of obesity-related diseases. Also provided are a pharmaceutical composition, a medicament, a food product, and an animal feed that comprise Bacteroides, uses thereof in treatment or prevention of obesity-related diseases, and a method for treatment or prevention of obesity-related diseases.

The present invention relates to a lactic acid fermented product of cassia seeds. The fermented product of the present invention uses cassia seeds, which have long been used and have proven their safety without causing side effects. Due to this advantage, the lactic acid fermented product of the present invention is effective in increasing the number, water content, and/or weight of feces. The effects of the lactic acid fermented product according to the present invention are comparable to those of sennoside, which is a therapeutic agent for stimulant constipation and whose use in health functional foods is forbidden because of its side effects, and Dulcolax-S, which is currently commercially available and includes bisacodyl and sodium docusate as active ingredients. Therefore, the lactic acid fermented product of the present invention can be utilized in pharmaceutical compositions for treating or preventing constipation or health functional foods for ameliorating or preventing constipation. In addition, the present invention relates to Lactobacillus kefiri strain MJ90. The strain is advantageous for the preparation of the lactic acid fermented product with enhanced activity in the treatment, amelioration or prevention of constipation.

The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection. Therefore, Lactobacillus rhamnosus CCFM1119 has great application prospects in the preparation of products (such as food or medicine) for preventing and/or treating Helicobacter pylori infection.

Provided herein are pharmaceutical compositions comprising a bacterial consortium and one or more pharmaceutically acceptable excipients. Such pharmaceutical compositions can be orally administered to a subject for prevention and/or treatment of dysbiosis, dysbiosis associated conditions, inflammation, and autoimmune diseases.

A composition for promoting defecation includes a cell culture of at least one lactic acid bacterial strain which is substantially free of cells. The least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9, and Lactobacillus acidophilus TYCA06, which are respectively deposited at the Bioresource Collection and Research Center (BCRC) under accession numbers BCRC 910437, BCRC 910645 and BCRC 910813. Also disclosed is a method for promoting defecation, including administering to a subject in need thereof an effective amount of the composition.